Drug intelligence / Profile preview

chidamide + cisplatin

Development stage: Unknown
Lead developer: Akeso
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Chidamide + cisplatin is a combination therapy consisting of chidamide, a novel histone deacetylase (HDAC) inhibitor that selectively inhibits HDAC1, 2, 3, and 10, and cisplatin, a platinum-based chemotherapy drug. Chidamide belongs to the benzamide chemical class of HDAC inhibitors. Preclinical studies showed that chidamide could enhance platinum-induced cytotoxicity at non-toxic doses. This combination was investigated for its potential synergistic effects in cancer treatment, particularly for triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

Targets

HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)DNA

Beyond the preview

Go deeper on chidamide + cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chidamide + cisplatin.

Explore the full profile